Evidence map›Paper›PMID 39339222›Full record

ArticlePharmaceutics2024

Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kg.

Klervi Golhen, Michael Buettcher, Jörg Huwyler, John van den Anker, Verena Gotta, Kim Dao, Laura E Rothuizen, Kevin Kobylinski, Marc Pfister

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Klervi GolhenPediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, 4056 Basel, Switzerland.ORCID 0009-0009-3738-7257
Michael BuettcherPediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, 4056 Basel, Switzerland.ORCID 0000-0001-6086-6162
Jörg HuwylerDepartment of Pharmaceutical Sciences, Division of Pharmaceutical Technology, University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-1748-5676
John van den AnkerPediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, 4056 Basel, Switzerland.
Verena GottaPediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, 4056 Basel, Switzerland.ORCID 0000-0001-6254-5207
Kim DaoClinical Pharmacology Service, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-6033-3435
Laura E RothuizenClinical Pharmacology Service, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland.
Kevin KobylinskiMahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok 10400, Thailand.
Marc PfisterPediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel (UKBB), University of Basel, 4056 Basel, Switzerland.ORCID 0000-0003-2597-1228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antiparasitic drug ivermectin is approved for persons > 15 kg in the US and EU. A pharmacometric (PMX) population model with clinical PK data was developed (i) to characterize the effect of the patient-friendly ivermectin formulation CHILD-IVITAB on the absorption process and (ii) to evaluate dosing for studies in children < 15 kg. Simulations were performed to identify dosing with CHILD-IVITAB associated with similar exposure coverage in children ≥ 15 kg and < 15 kg as observed in adults receiving the reference formulation STROMECTOL

Indexed as

absorptiondosingivermectinnovel delivery systemsoral drug deliveryorodispersible tablet (ODT)pharmacometricsSTROMECTOL®TIP-based technologyvariability

Identifiers

PMID39339222
PMCPMC11435260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.